November 14, 2022 Asieris named “2022 TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs”
November 11, 2022 The Oral APL-1202 in Combination with PD-1 inhibitor Tislelizumab as Neoadjuvant Therapy has Entered Phase II Clinical Study
November 10, 2022 Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
November 4, 2022 Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial